A7856
Acipimox
≥99% (TLC)
Synonym(s):
2-Carboxy-5-methylpyrazine 4-oxide, 5-Methylpyrazinecarboxylic acid 4-oxide
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
| Pack Size | SKU | Availability | Price |
|---|
About This Item
Empirical Formula (Hill Notation):
C6H6N2O3
CAS Number:
Molecular Weight:
154.12
MDL number:
UNSPSC Code:
12352205
EC Number:
256-928-3
NACRES:
NA.79
Pricing and availability is not currently available.
assay
≥99% (TLC)
form
powder
color
off-white to faint yellow
mp
177-180 °C
storage temp.
2-8°C
SMILES string
[n+]1(c(cncc1C(=O)O)C)[O-]
InChI
1S/C6H6N2O3/c1-4-2-7-3-5(6(9)10)8(4)11/h2-3H,1H3,(H,9,10)
InChI key
DNRXJHATQULEHC-UHFFFAOYSA-N
Biochem/physiol Actions
Niacin-derived, vasodilator studied for its lipid-lowering effect.
Acipimox, also known as olbemox, is a nicotinic acid analog. It functions as an anti-lipolytic drug and vasodilator. Acipimox may be used in various metabolic studies involving insulin and ghrelin. It lowers total cholesterol and total triglycerides, which helps in the treatment of hyperlipidemia.
1 of 1
This Item | |||
|---|---|---|---|
| assay ≥99% (TLC) | assay ≥98% (HPLC) | assay ≥98% (TLC) | assay ≥98% (HPLC) |
| form powder | form powder | form powder | form powder |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. - | storage temp. 2-8°C |
| mp 177-180 °C | mp - | mp - | mp - |
| color off-white to faint yellow | color white to beige | color - | color white to beige |
Still not finding the right product?
Explore all of our products under Acipimox
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Mads Halbirk et al.
American journal of physiology. Heart and circulatory physiology, 299(4), H1220-H1225 (2010-08-17)
Circulating free fatty acids (FFAs) may worsen heart failure (HF) due to myocardial lipotoxicity and impaired energy generation. We studied cardiac and whole body effects of 28 days of suppression of circulating FFAs with acipimox in patients with chronic HF.
Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression
Cordido F, et al.
The Journal of clinical endocrinology and metabolism, 81(3), 914-918 (1996)
Fabrizio Montecucco et al.
American journal of physiology. Endocrinology and metabolism, 300(4), E681-E690 (2011-01-27)
Metabolic syndrome is a proatherosclerotic condition clustering cardiovascular risk factors, including glucose and lipid profile alterations. The pathophysiological mechanisms favoring atherosclerotic inflammation in the metabolic syndrome remain elusive. Here, we investigated the potential role of the antilipolytic drug acipimox on
Global Trade Item Number
| SKU | GTIN |
|---|---|
| A7856-1G | 04061826648445 |